Research we’re watching: No heart risk-or benefit-from diabetes drug Onglyza

In the largest and most comprehensive study of the heart effects of a diabetes drug, the blood sugar-lowering drug saxagliptin (Onglyza) showed no benefit in protecting against heart disease or stroke. Importantly, the drug also did not increase cardiovas